Top Story

Steady $7.7 billion market projected for colorectal cancer therapy through 2023

September 2, 2014

The colorectal cancer therapeutics market will remain steady at approximately $7.7 billion by 2023 in the US, France, Germany, Italy, Spain, the United Kingdom and Japan, according to a Decision Resources Group press release.

The report predicts that the biosimilar erosion of key agents, namely Avastin (Roche, Genentech, Chugai) and Erbitux (Bristol-Myers Squibb, Eli Lilly, Merck KgaA), will be offset by the launch of premium-priced therapies such as Cyramza (Eli Lilly), Lonsurf (Taiho Pharmaceuticals), HA-irinotecan (Alchemia) and Vargatef (Boehringer Ingelheim) and by increased utilization of Zaltrap (Sanofi, Regeneron) and Vectibix (Amgen, Takeda).

figure In the Journals

One in four patients with head, neck cancers do not receive guideline-directed adjuvant therapy

September 2, 2014
About 25% of patients with surgically resected head and neck cancers that exhibit adverse pathologic features do not receive guideline-directed adjuvant therapy with…
figure In the Journals

Hispanic veterans with HCV at higher risk for cirrhosis, HCC

September 1, 2014
Hispanic veterans with hepatitis C virus infection had a higher risk for developing cirrhosis or hepatocellular carcinoma compared with African-American and non-Hispanic…
In the Journals

Surgery remains ‘gold standard’ for basal cell carcinoma

September 1, 2014
Surgery remains the ideal treatment for patients with basal cell carcinoma, according to results of an evidence review.Researchers with Columbia University Medical…
More News Headlines »
CME

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

8/16/2014
Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
figure

Docetaxel plus ADT improved OS in metastatic prostate cancer

June 24, 2014
CHICAGO — Donald L. Trump, MD, FACP, president and CEO at Roswell Park Cancer Institute and HemOnc Today
More »
CME CNE

Treatment Decision-Making through the Spectrum of MDS: Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

8/20/2014
MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »